By 2030, an estimated 30 million people in the United States (~9% of the population) are expected to use GLP1-RA drugs, highlighting their role in addressing obesity and expanding therapeutic applications13,14. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.